Markets:

Overview

News

Currencies

International

Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

79.66 +2.68 (+3.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Tarsus to Present at Upcoming Investor Conferences

August 30, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

August 24, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals ↗

August 14, 2023

Via Benzinga

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

August 10, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know ↗

July 26, 2023

Via Benzinga

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

August 01, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 01, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 31, 2023

Via Benzinga

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

July 31, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown ↗

July 25, 2023

The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 25, 2023

Via Benzinga

Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 25, 2023

Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.

Via Benzinga

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

July 25, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Why Shares of Tarsus Pharmaceuticals Are Up Thursday ↗

July 20, 2023

The company's lead therapy is getting close to the finish line of FDA approval.

Via The Motley Fool

Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 20, 2023

Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.

Via Benzinga

Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High

July 20, 2023

Via Investor Brand Network

Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday ↗

July 20, 2023

U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose...

Via Benzinga

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

June 12, 2023

Webcast scheduled for Thursday, June 15 at 8:30am PT

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Present at the Jefferies Global Healthcare Conference

June 05, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗

July 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗

May 18, 2023

Via Benzinga

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

May 09, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

May 08, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

May 03, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

April 24, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay ↗

April 18, 2023

Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).

Via Benzinga

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗

March 28, 2023

Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...

Via Benzinga

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

March 13, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

March 02, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today